CompanyGraph
Kingchem Liaoning Life Science Co., Ltd.
301509 · SZSE · China
kingchemchina.comFinancials as of FY2025
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleLevered free cash flow is $94.58M, above the global median of $16.24M
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
2.74%
Annual Rate
CNY 0.90Paid annual
Payout Ratio
64.5%Moderate
Payback Period
34.2 yr
Last Ex-Dividend
Jun 2, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
3.72BCNY552.76M · vs all stocks (USD)
Trailing P/E
51.90xRevenue (TTM)
611.14MCNY90.77M · vs all stocks (USD)
Profit Margin
12.11%Beta
0.3080xvs all stocks
52-Week Change
-25.03%vs all stocks
Market Capitalization
3.72BCNY552.76M · vs all stocks (USD)
Enterprise Value
2.84BCNY422.02M · vs all stocks (USD)
Trailing P/E
51.90xPrice to Sales (TTM)
6.34xPrice to Book (MRQ)
1.74xEnterprise to Revenue
4.65xEnterprise to EBITDA
23.49xGross Margin
42.34%Profit Margin
12.11%Operating Margin
13.64%Return on Assets (TTM)
1.67%Return on Equity (TTM)
3.35%Revenue (TTM)
611.14MCNY90.77M · vs all stocks (USD)
Revenue per Share (TTM)
5.10CNYUpdated Aug 20, 2026Quarterly Revenue Growth
-16.00%Gross Profit (TTM)
227.61MCNY33.80M · vs all stocks (USD)
EBITDA (TTM)
120.08MCNY17.83M · vs all stocks (USD)
Net Income (TTM)
74.03MCNY11.00M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-64.90%Operating Cash Flow (TTM)
140.15MCNY20.82M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
636.84MCNY94.58M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.9000CNYUpdated Aug 20, 2026Trailing Annual Dividend Yield
2.74%vs all stocks
Payout Ratio
64.52%Revenue
639.37MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
367.70MCNYFY2025 · Dec 31, 2025Gross Profit
271.67MCNYFY2025 · Dec 31, 2025Operating Income
113.51MCNY16.86M · vs all stocks (USD)
Pre-tax Income
120.92MCNYFY2025 · Dec 31, 2025Income Tax Expense
16.11MCNYFY2025 · Dec 31, 2025Net Income
104.81MCNYFY2025 · Dec 31, 2025EBIT
121.11MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
198.38MCNYFY2025 · Dec 31, 2025Research & Development
35.91MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
34.09MCNYFY2025 · Dec 31, 2025Other Operating Expenses
10.31MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
10.06MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
193.02KCNYFY2025 · Dec 31, 2025EPS (Basic)
0.8700CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.8700CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
120.47MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
120.47MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
104.81MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-80.56MCNYFY2025 · Dec 31, 2025Free Cash Flow
-122.38MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
370.74MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
104.81MCNYFY2025 · Dec 31, 2025Other Non-cash Items
7.43MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-237.37MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
44.56MCNYFY2025 · Dec 31, 2025Capital Expenditures
-41.81MCNYFY2025 · Dec 31, 2025Sale of Investments
20.41MCNYFY2025 · Dec 31, 2025Other Investing Activity
85.79MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
64.39MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-48.37MCNYFY2025 · Dec 31, 2025Other Financing Charges
-1.93MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-50.30MCNYFY2025 · Dec 31, 2025Shares Outstanding
120.45MSharesUpdated Aug 20, 2026Float Shares
56.74MSharesUpdated Aug 20, 2026% Held by Insiders
56.10%vs all stocks
% Held by Institutions
5.73%vs all stocks
Total Cash (MRQ)
1.11BCNY164.29M · vs all stocks (USD)
Total Cash per Share (MRQ)
9.18CNYUpdated Aug 20, 2026Total Debt (MRQ)
3.01MCNY447.23K · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0014xCurrent Ratio (MRQ)
16.57xBook Value per Share (MRQ)
18.45CNYUpdated Aug 20, 2026Total Assets
2.32BCNY344.53M · vs all stocks (USD)
Total Current Assets
1.61BCNYFY2025 · Dec 31, 2025Total Liabilities
112.70MCNYFY2025 · Dec 31, 2025Total Non-current Assets
708.24MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
19.37MCNYFY2025 · Dec 31, 2025Total Current Liabilities
93.33MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
370.74MCNYFY2025 · Dec 31, 2025Other Short-term Investments
713.06MCNYFY2025 · Dec 31, 2025Accounts Receivable
106.13MCNYFY2025 · Dec 31, 2025Inventory
144.68MCNYFY2025 · Dec 31, 2025Accounts Payable
42.53MCNYFY2025 · Dec 31, 2025Short-term Debt
1.40MCNYFY2025 · Dec 31, 2025Other Current Liabilities
859.00CNYFY2025 · Dec 31, 2025Long-term Debt
1.82MCNYFY2025 · Dec 31, 2025Common Stock (Book)
120.45MCNYFY2025 · Dec 31, 2025Retained Earnings
417.52MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
2.21BCNY327.79M · vs all stocks (USD)
52-Week Low
25.65CNYUpdated Aug 20, 202652-Week High
48.60CNYUpdated Aug 20, 202652-Week Change
-25.03%vs all stocks
Beta
0.3080xvs all stocks
50-Day MA
29.11CNYUpdated Aug 20, 2026200-Day MA
34.83CNYUpdated Aug 20, 2026Avg 10-Day Volume
5.89MSharesUpdated Aug 20, 2026Avg 30-Day Volume
4.27MSharesUpdated Aug 20, 2026Diluted EPS (TTM)
0.6200CNYUpdated Aug 20, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Levered free cash flow is $94.58M, above the global median of $16.24MNotable
Levered free cash flow (USD): 94,583,011.041Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Nanjing Well Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Altimmune, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Orchid Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Relmada Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Morepen Laboratories Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Assure Tech Hangzhou Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Boryung Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
NeuroPace Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Sailun Biotech Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
CHA Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleInterface